HYBIO(SZ:300199) 智通财经网·2025-06-30 13:08Group 1 - CITIC Securities has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 30 billion yuan [1] - The bonds can be issued in tranches within 24 months from the date of approval [1] Group 2 - Silan Microelectronics' shareholder, Luo Huabing, plans to reduce his holdings by no more than 500,000 shares, accounting for up to 0.03005% of the company's total share capital [2] - The reduction will occur within three months after a 15 trading day period from the announcement date [2] Group 3 - Sanofi Biologics' subsidiary has received a drug registration certificate for its injection product, which is a GLP-1 analog for improving blood sugar control in type 2 diabetes patients [3] - This certification enhances the company's product portfolio in the diabetes medication sector, positively impacting future performance [3] Group 4 - Lens Technology announced a global offering of H-shares with a base issuance of 262 million shares, with an initial price range set between 17.38 and 18.18 HKD [4] - The H-shares are expected to be listed on the Hong Kong Stock Exchange on July 9, 2025 [4] Group 5 - Huitian Ruisheng's controlling shareholder, He Lin, plans to reduce his holdings by up to 2.95% of the company's total shares, amounting to 177,740 shares [5] - Other executives also plan to reduce their holdings within a similar timeframe [5] Group 6 - Hongxin Electronics' subsidiaries signed contracts totaling 373 million yuan for AI-related services, indicating growth in the AI business sector [6] Group 7 - Hangzhou High-tech is planning a change in control, with the actual controller Hu Min intending to transfer 19.03% of the company's shares [7] - The stock is expected to be suspended for no more than two trading days [7] Group 8 - Junpu Intelligent signed a sales framework contract for humanoid robots worth approximately 28.25 million yuan [8] Group 9 - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock resuming trading on July 1, 2025 [9] Group 10 - He Shi Eye Hospital's major shareholder plans to reduce holdings by up to 2% of the company's shares, totaling 310,610 shares [10] Group 11 - Prit's investment of 1 billion yuan in a new manufacturing base in Guangzhou is expected to produce 400,000 tons annually, focusing on non-automotive applications [11] Group 12 - Tongfu Microelectronics reported a 1% reduction in shares by the National Integrated Circuit Industry Investment Fund, decreasing its holding from 8.77% to 7.77% [12] Group 13 - Jinpu Titanium Industry plans to acquire the equity of Lide Dongfang through a major asset swap and cash payment, with stock suspension starting July 1, 2025 [13] Group 14 - Several companies have reported expected profit increases for the first half of the year, with notable growth percentages [16]